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Coronary artery disease (CAD) is a major cause of morbidity and mortality. Mutations in C6ORF105,
associated with decreased gene expression, positively correlate with the risk of CAD in Chinese pop-
ulations. Moreover, the C6ORF105-encoded protein may play a role in coagulation. Here, we report
that C6ORF105 gene expression is lower in circulating mononuclear cells from obese diabetic than
lean subjects. Moreover, C6ORF105 is expressed in human macrophages and atherosclerotic lesions,
where its expression positively correlates with expression of the transcription factor Peroxisome
Proliferator-Activated Receptor (PPAR)c. Activation of PPARc increases, in a PPARc-dependent
manner, the expression of C6ORF105 in human macrophages and atherosclerotic lesions.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Coronary artery diseases (CAD) are amongst the major causes of
morbidity and mortality in western countries. The pathogenesis of
CAD is inﬂuenced by the interaction of environmental and genetic
factors. Genome-wide association studies (GWAS) in Chinese
populations, identiﬁed a single nucleotide polymorphism (SNP),
designated rs6903956, in a putative gene denoted as C6ORF105
on chromosome 6p24.1 leading to decreased C6ORF105 gene
expression [1]. Interestingly, this mutation in C6ORF105 is strongly
associated with the risk of CAD, an association that remains
signiﬁcant after adjustment for other covariates (age, sex, diabetes,
lipids, hypertension) [1].
Information on the structure and functions of C6ORF105 is
however limited. C6ORF105 shares 51% homology with the humanandrogen-inducible gene 1 product (AIG-1) [1]. The predicted pro-
tein encoded by this gene likely exists in two isoforms with 3-6
transmembrane domains [2]. Data mining approaches showed that
C6ORF105 gene coexpresses and correlates with the gene expres-
sion of the Tissue Factor Pathway Inhibitor (TFPI) [2], an inhibitor
of the Tissue Factor (TF) pathway [3]. Thus the protein encoded by
C6ORF105 is an androgen controlled membrane protein regulating
TFPI expression and function in endothelial cells, therefore termed
androgen-dependent TFPI-regulating protein (ADTRP) [2].
Macrophages play crucial roles in the pathogenesis of
atherosclerosis by controlling the inﬂammatory response and lipid
handling (cholesterol accumulation, trafﬁcking and efﬂux). Tissue
macrophages are heterogeneous cells adapting their activation
and functional phenotype to the microenvironment [4]. Indeed,
pro-inﬂammatory stimuli, such as interferon c (IFNc), interleu-
kin-1b (IL-1b) or lipopolysaccharide (LPS), drive macrophages
toward a classical M1 activation proﬁle characterized by the
expression of pro-inﬂammatory molecules. By contrast, signals
such as IL-4 and IL-13, lead to an alternative M2 activation pro-
gram in macrophages that produce anti-inﬂammatory mediators
(IL-10, transforming growth factor-b (TGF-b) and IL-1 receptor
antagonist (IL-1Ra)), scavenge debris and promote angiogenesis,
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are present in human atherosclerotic lesions, where their relative
proportion might inﬂuence plaque stability and progression [7].
The Peroxisome Proliferator-Activated Receptors (PPARs)
PPARa, PPARb/d, and PPARc, are transcription factors activated by
fatty acids and fatty acid-derived eicosanoids. PPARs exhibit com-
mon but also distinct functions: PPARa regulates lipid oxidation
and inﬂammation, mainly in hepatocytes, whereas PPARc controls
lipid storage, exerts anti-inﬂammatory activities and promotes pre-
adipocyte differentiation into adipocytes [8] and PPARb/d controls
fatty acid oxidation notably in skeletal muscle [9,10]. Moreover,
PPARs are expressed in macrophages where they control the
inﬂammatory response and cholesterol metabolism [11].
While C6ORF105 appears as a novel CAD associated gene, no
data are currently available regarding its expression and regulation
in macrophages. In this paper we study the expression of
C6ORF105 in primary human macrophages and atherosclerotic
lesions and analyse its regulation by PPAR ligands.
2. Materials and methods
2.1. Endarterectomy tissue samples
Human atherosclerotic plaques were removed from patients
eligible for surgical carotid endarterectomy recruited at the Cardio-
vascular Surgery Department, Hospital of Lille, France, [12] or wereR= 0.76
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artery stenosis randomized to 4 weeks placebo or rosiglitazone
before surgery recruited at the Department of Thoracic and
Vascular Surgery, University of Ulm, Germany [13]. Written
informed consent was obtained from all subjects. Immediately
after endarterectomy, carotid atherosclerotic plaques were frozen
in liquid nitrogen.
2.2. Immunohistochemical analysis
Carotid atherosclerotic plaques were frozen in liquid nitrogen
immediately after endarterectomy. A fragment of the plaque was
used for total RNA extraction. For immunohistochemical analysis
performed on serial 10 lm-cryosections, endogenous peroxidase
activity was quenched and sections stained with anti-C60RF105
(Sigma) or with anti-CD68 (Dako) antibodies, with N-Histoﬁne
Simple Stain MAX PO as polymer (Nichirei Biosciences Inc.) and
Vector Nova Red (Vector) as substrate.
2.3. Cell culture
Peripheral blood was drawn from consenting diabetic obese
patients during the pre-operative clinic visit and from lean control
subjects enrolled in the ABOS study at the Department of
Endocrine Surgery, Lille University Hospital, France. Morbidly
obese diabetic female patients (BMI > 35, glycemiaP 7 mmol/l100 µm
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group of lean normoglycemic individuals operated for benign and
non-inﬂammatory diseases (BMI6 27, glycemia 6 6 mmol/l fasting
and/or6 7.8 mmol/l 120 min after glucose loading) were studied.
Human peripheral blood mononuclear cells (PBMC) were iso-
lated by density gradient centrifugation and monocytes were dif-
ferentiated into macrophages by 7 days of culture in RPMI1640
medium (Invitrogen, France) supplemented with gentamicin
(40 lg/ml), L-glutamine (2 mM) (Sigma–Aldrich, France) and 10%
human serum (Abcys, France) [14]. M2 macrophages were
obtained by differentiating monocytes in the presence of human
IL-4 (15 ng/ml, Promocell, Germany) for 7 days, while M1 macro-
phages were obtained by activation of differentiated macrophages
with LPS (100 ng/ml, 4 h). Synthetic ligands for PPARc, GW1929
(600 nM) or rosiglitazone (100 nM), for PPARa (GW647, 600 nM)
and for PPARbd (GW1516, 100 nM) were added for 24 h at the
end of macrophage differentiation.
2.4. RNA extraction and analysis
Total cellular RNA was extracted using Trizol (Life Technologies,
France) and from human whole atherosclerotic plaques by the acid
guanidinium thiocyanate-phenol chloroform method [15]. RNA
was reverse transcribed and cDNAs quantiﬁed by Q-PCR on a
MX3000 apparatus (Stratagene) using speciﬁc primers (Table 1).
mRNA levels were normalized to those of cyclophilin. The relative
expression of each gene was calculated by the DCt method, where
DCt is the value obtained by subtracting the Ct (cycle threshold)R=  0.69
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Fig. 2. Expression of C6ORF105 correlates with PPARc and is induced by PPARc activa
(n = 24) and gene levels of C6ORF105, PPARc (A), PPARb/d (B) and PPARa (C) were measur
(D) QPCR analysis of C6ORF105 mRNA in human carotid atherosclerotic lesions from 7
sample; median value is indicated. Statistically signiﬁcant differences are indicated (paivalue of cyclophilin mRNA from the Ct value of the target gene.
The amount of target relative to the cyclophilin mRNA was
expressed as 2(DCt).2.5. Short-interfering (si)RNA assays
Differentiated RM macrophages were transfected with siRNA
speciﬁc for human PPARc and non-silencing control scrambled siR-
NA (Ambion), using the transfection reagent DharmaFECT4
(Dharmacon). After 16 h, cells were incubated with GW1929
(600nM) or vehicle (DMSO) and harvested 24 h later.
2.6. Adenovirus generation
The recombinant adenovirus (Ad)-GFP (Green Fluorescent Pro-
tein) and Ad-PPARc were obtained as described [16]. 1.5  106
macrophages were infected at a multiplicity of 100 viral parti-
cles/cell by adding virus stocks directly to the culture medium.
After 16 h of infection, cells were incubated for 24 h in the absence
or in the presence of GW1929 (600 nM).
2.7. Statistical analysis
Pearson correlation coefﬁcients (R) were calculated from Q-PCR
DCt data. Statistical differences between groups were analyzed by
Mann Whitney-test or Student’s t test and considered signiﬁcant
when P < 0.05.*
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3.1. C6ORF105 is expressed in circulating mononuclear cells and in
human atherosclerotic plaque macrophages
Mutations leading to a reduced C6ORF105 expression levels
have been associated to an increased risk for CAD in Chinese
populations [1]. While it is known that C6ORF105 is expressed in
the heart, stomach skin and kidney as well as in leukocytes [1],
no information is available regarding its expression neither in mac-
rophages nor in atherosclerotic lesions. Therefore, we wondered
whether C6ORF105 is expressed in monocyte/macrophages and
regulated in different pathological conditions such as obesity and
atherosclerosis. First, gene expression of C6ORF105 was analysed
in PBMC isolated from lean or obese diabetic subjects, which are
at increased risk of CAD [17]. While C6ORF105 gene expression
was generally low in PBMC, even lower levels of expression were
observed in mononuclear cells from obese diabetics, compared to
lean individuals (Fig. 1A). Comparison of gene expression levels
in healthy zones and adjacent atherosclerotic plaques isolated dur-
ing endarterectomy, revealed that the expression of C6ORF105
gene was found to be higher in pathological compared to healthy
zones (Fig. 1B). Interestingly, a strong positive correlation was
observed between the expression levels of C6ORF105 and thoseA
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Fig. 3. Expression of C6ORF105 is induced by PPARc activation in human primary macro
presence of GW1929 (600 nM) for 24 or 48 h. (B) Differentiated macrophages were tr
GW1929 (600 nM) or DMSO during 24 h. (C) Humanmacrophages were infected with a G
with Rosiglitazone (100 nM). (D) Primary human monocytes were differentiated to res
7 days (M2) and then treated for 24 h with GW1929 (600 nM). Where indicated, RM were
(600 nM). Results are representative of those obtained from 3 independent macrophage
bar is the mean value ± S.D. of triplicate determinations. Statistically signiﬁcant differenof CD68, a marker of macrophages within the atherosclerotic
lesions (Fig. 1C), thus suggesting that macrophages may be a major
source of C6ORF105 within the atherosclerotic plaques. Immuno-
histological analysis conﬁrmed that C6ORF105 is indeed expressed
by macrophages within the atherosclerotic plaques (Fig. 1D). Our
data provide the ﬁrst evidence for the expression of C6ORF105
in vivo in macrophages resident in atherosclerotic plaques.
3.2. Expression of C6ORF105 in human atherosclerotic plaques
correlates with PPARc expression and is induced upon PPARc
activation
Since transcription factors, such as PPAR family members, play
an important role in the control of macrophage gene expression
and functions, a correlation analysis was performed between the
expression levels of C6ORF105 and the three members of the PPAR
family. In human atherosclerotic lesions, PPARc expression posi-
tively correlates with C6ORF105 expression (R = 0.69) (Fig. 2A).
Moreover, C6ORF105 expression within the plaque also correlates
with PPARb/d expression (R = 0.49) (Fig. 2B), while the correlation
with PPARa was less pronounced (R = 0.24) (Fig. 2C). Finally,
C6ORF105 expression was signiﬁcantly induced in vivo in athero-
sclerotic plaques isolated from subjects treated with rosiglitazone
for 4 weeks when compared to placebo treatment (Fig. 2D). TheseC
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correlates with PPARc and is induced by PPARc activation.3.3. Activation of PPAR increases the expression of C6ORF105 in
primary human macrophages
In vitro studies performed in human primary differentiated
macrophages showed that C6ORF105 expression is also induced
in vitro by the synthetic PPARc ligand GW929 (Fig. 3A). PPARc
siRNA knockdown conﬁrmed that these effects are mediated by
PPARc since the induction of C6ORF105 was signiﬁcantly reduced
in the presence of the PPARc siRNA (Fig. 3B). Complementary gain
of function experiments using an adenovirus coding for PPARc
(Ad-PPARc) showed that the induction of C6ORF105 gene expres-
sion by the PPARc ligand rosiglitazone was signiﬁcantly enhanced
in Ad-PPARc-infected macrophages (Fig. 3C). Moreover, in human
primary macrophages in vitro, PPARa and PPARb/d activation
signiﬁcantly increased C6ORF105 expression albeit it to a lower
extent than with PPARc ligands (Supplemental Fig. 1A). Expression
of CPT-1, a well known target gene for PPAR activation, was
measured as positive control of ligand activation efﬁciency
(Supplemental Fig. 1B).
Since macrophages can display different phenotype depending
on their environment [18], the regulation of C6ORF105 by PPARc
ligands observed in non-polarized macrophages (RM) was also
studied in pro-inﬂammatory M1 and in anti-inﬂammatory M2
macrophages. While the basal expression level of C6ORF105 was
not affected by the macrophage polarization state, PPARc
activation induced C6ORF105 gene expression in all macrophage
sub-types with the largest effect observed in M1 macrophages.
Decreased expression of C6ORF105 has been suggested to be a
possible pathogenic cause of CAD, at least in Chinese populations
[1]. At present, the rs6903956 SNP has not yet been identiﬁed as
a susceptibility locus in European populations. This suggests that
the association between rs6903956 and CAD may be limited to
Chinese populations and may not be of importance in other ethnic
populations. However, here we report that C6ORF105 expression is
lower in circulating blood mononuclear cells of obese diabetic sub-
jects compared to lean individuals, all from European origin, an
observation in line with the increased CAD risk proﬁle of this group
of subjects [17]. C6ORF105 shares 51% homology with the human
androgen-inducible gene 1 product (AIG-1) [1]. AIG-1 expression
can be induced by androgens in cultured human dermal papilla
cells [19], but little is known regarding its function. Recently,
C6ORF105 expression gene has been found to positively correlate
with TFPI and the protein encoded by C6ORF105 (named ADTRP)
has been shown to mediate the induction of TFPI expression and
activity by androgens in endothelial cells [2].
We now report that C6ORF105 gene is expressed in primary
human macrophages, irrespective of their phenotype as well as
in human atherosclerotic lesions. Besides androgens, we show that
ligands of the PPAR nuclear receptors, and in particular PPARc,
enhance macrophage expression of C6ORF105 in vitro and in vivo
in human atherosclerotic lesions.
Further, functional studies will be necessary to understand
the exact role of C6ORF105 in macrophages. However, the fact that
the C6ORF105 protein may be involved in the regulation of the
coagulation inhibitor TFPI might provide a mechanism for the asso-
ciation between CAD risk and reduced C6ORF105 expression.
Indeed, TF-driven blood coagulation not properly countered by
TFPI can lead to thrombotic events [20] precipitating CAD associ-
ated complications, thus increasing CAD risk. Interestingly, data
available in the literature and our own unpublished results
indicate that PPARc ligands induce TFPI secretion by human endo-
thelial cells [21] and macrophages.Acknowledgements
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Supplementary data associated with this article can be found, in
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